Loading...

Shionogi & Co., Ltd.

SGIOYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$8.70
$0.03(0.37%)

Shionogi & Co., Ltd. (SGIOY) Financial Performance & Income Statement Overview

Analyze Shionogi & Co., Ltd. (SGIOY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
0.73%
0.73%
Operating Income Growth
-6.81%
6.81%
Net Income Growth
5.19%
5.19%
Operating Cash Flow Growth
26.69%
26.69%
Operating Margin
26.59%
26.59%
Gross Margin
84.30%
84.30%
Net Profit Margin
33.42%
33.42%
ROE
5.07%
5.07%
ROIC
3.70%
3.70%

Shionogi & Co., Ltd. (SGIOY) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Shionogi & Co., Ltd. SGIOY financial performance.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$104.67B$119.63B$116.38B$97.59B
Cost of Revenue$18.71B$15.90B$16.77B$14.44B
Gross Profit$85.95B$103.73B$99.62B$83.14B
Gross Profit Ratio$0.82$0.87$0.86$0.85
R&D Expenses$29.16B$22.62B$27.39B$29.43B
SG&A Expenses$28.69B$25.45B$23.69B$24.04B
Operating Expenses$57.85B$50.38B$51.09B$55.03B
Total Costs & Expenses$76.57B$66.28B$67.85B$69.48B
Interest Income$20.16B$9.44B$12.32B$11.25B
Interest Expense$2.67B$751.00M$2.77B$2.84B
Depreciation & Amortization$5.21B$5.44B$5.37B$4.92B
EBITDA$52.75B$58.79B$65.45B$33.03B
EBITDA Ratio$0.50$0.49$0.56$0.34
Operating Income$28.10B$53.35B$48.53B$28.11B
Operating Income Ratio$0.27$0.45$0.42$0.29
Other Income/Expenses (Net)$16.77B$8.69B$8.78B$8.41B
Income Before Tax$44.87B$62.04B$57.31B$36.52B
Income Before Tax Ratio$0.43$0.52$0.49$0.37
Income Tax Expense$8.68B$11.58B$4.74B$6.22B
Net Income$36.63B$50.67B$52.50B$30.64B
Net Income Ratio$0.35$0.42$0.45$0.31
EPS$43.02$59.55$61.70$36.02
Diluted EPS$43.02$59.55$61.70$36.01
Weighted Avg Shares Outstanding$850.69M$850.88M$850.79M$850.79M
Weighted Avg Shares Outstanding (Diluted)$850.69M$850.88M$850.79M$850.79M

Over the last four quarters, Shionogi & Co., Ltd.'s revenue moved from $97.59B in Q1 2024 to $104.67B in Q4 2024. Operating income in Q4 2024 was $28.10B, with a strong operating margin of 27%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Shionogi & Co., Ltd. remained robust at $52.75B, reflecting operational efficiency. Net income dropped to $36.63B, with an EPS of $43.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;